ACOG Recommends Delayed Umbilical Cord Clamping

Share this content:
ACOG Recommends Delayed Umbilical Cord Clamping
ACOG Recommends Delayed Umbilical Cord Clamping

WEDNESDAY, Dec. 21, 2016 (HealthDay News) -- Delayed umbilical cord clamping is beneficial for most term and preterm infants, according to a Committee Opinion from the American College of Obstetrics and Gynecology (ACOG) published in the January issue of Obstetrics & Gynecology.

Maria A. Mascola, M.D., from the ACOG Committee on Obstetric Practice, and colleagues made recommendations on delayed umbilical cord clamping after birth.

The authors note that for term and preterm infants, delayed cord clamping seems to be beneficial. Delayed clamping is associated with increases in hemoglobin levels at birth and improved iron stores in the first months of life in term infants. This group of infants has a small increase in jaundice requiring phototherapy, and therefore mechanisms should be in place to monitor for and treat neonatal jaundice. Delayed clamping is associated with significant neonatal benefits in preterm infants, including improved transitional circulation, better establishment of red blood cell volume, decreased need for blood transfusion, and lower incidence of necrotizing enterocolitis and intraventricular hemorrhage. There was no association for delayed clamping with increased risk of postpartum hemorrhage or increased blood loss at delivery, nor was there any correlation with postpartum hemoglobin levels or the need for blood transfusion.

"Given the benefits to most newborns and concordant with other professional organizations, the American College of Obstetricians and Gynecologists now recommends a delay in umbilical cord clamping in vigorous term and preterm infants for at least 30 to 60 seconds after birth," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »